-+ 0.00%
-+ 0.00%
-+ 0.00%

What Eli Lilly Buyers Were Betting On

Simply Wall St·11/18/2026 23:19:07
Listen to the news

If you only glanced at Eli Lilly’s headlines this year, the focus was on soaring GLP-1 revenues, fresh acquisitions across vaccines, oncology, and neuroscience, and raised guidance for 2026. Holding Eli Lilly over the past year would have returned 32.5%, including dividends. If you had been weighing that decision back on 18 November 2025, with fierce competition, pricing pressure, and concentration risk in view, what exactly in the record justified taking that ride?

Eli Lilly is not the only name tied to this theme. Zero in on 37 healthcare AI stocks and compare how each one is priced.

The Two Stories Investors Had To Choose Between On Eli Lilly

The shares cost US$1,030 at the start of the period, which left you deciding whether Eli Lilly was priced for steady execution or something more ambitious around obesity and aging trends.

On the bullish side, one narrative pointed to a Fair Value of US$1,190. This was a price that reflected expectations rather than a given outcome, built on oral GLP-1s like orforglipron and small molecule manufacturing enabling mass-market obesity treatment.

The more cautious view anchored on a Fair Value of US$892, again an implied figure not a fact, and stressed concentration in blockbuster incretins and the risk that pricing reform and payer pushback could squeeze margins.

NYSE:LLY 1-Year Stock Price Chart
NYSE:LLY 1-Year Stock Price Chart

What The Evidence Did To The Eli Lilly Argument

The standout fact arrived in Q3 2026, when Eli Lilly’s revenue was US$24,397m versus US$17,601m a year earlier, with net income also higher. That outcome backed the bullish story around GLP-1 demand and pipeline execution, although the drop in net margin from 31.7% to 26.4% challenged the idea of effortless profitability expansion. Overall, the period cut both ways.

The lesson is simple. When a thesis leans on margin strength, do not stop at top-line gains. Track net margin alongside sales and ask whether each extra dollar of revenue is earning more or less profit over time.

What Eli Lilly’s Price Asks You To Believe Today

Eli Lilly trades at US$1,383 today, after a 32.5% gain over the past year from US$1,030. The bearish analyst Narrative on Simply Wall St places its Fair Value below that price and frames the gap as a question about how much GLP-1 success is already assumed.

The same Narrative argues that current pricing only works if obesity and diabetes franchises keep scaling worldwide despite legal, reimbursement, and U.S. net price pressure. Anyone paying today effectively leans on incretin volume and access expanding fast enough to absorb large fixed manufacturing spend without squeezing profitability.

"While Eli Lilly is investing more than US$50b into global incretin manufacturing capacity, including a new US$6.5b Houston facility for oral GLP 1 supply, this fixed cost base could become a drag on net margins if pricing pressure on Mounjaro, Zepbound, Foundayo and future incretins continues and volume growth does not fully absorb the added overhead."

The price and this Narrative do not agree. → Uncover what this Narrative says Eli Lilly is actually worth

How Could You Get There Earlier?

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

  • Company 1 - 38% below our estimate - uses rapid store rollouts and app ordering to test dense coverage economics.
  • Company 2 - 49% below our estimate - builds a pipeline beyond cystic fibrosis through kidney, gene editing and endocrine programs.
  • Company 3 - 45% below our estimate - expands small business lending and deposits via digital onboarding and guaranteed loan platforms.

That is three of the list. See every one of the 35 undervalued companies on it →